In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with a price target of $22.00.
Andrew Fein has given his Buy rating due to a combination of factors that highlight the potential of Wave Life Sciences’ WVE-007. The company’s focus on the Activin Receptor II pathway, supported by fundamental biology and human genomics data, shows promise for the mechanism of action (MOA) of WVE-007. The ongoing INLIGHT trial, with data expected in the second half of 2025, further supports this optimism. Fein’s assessment is bolstered by insights from the Keystone Conference on Obesity, where discussions with key opinion leaders (KOLs) emphasized the strength of the scientific basis for targeting the INHBE program.
Preclinical data, including studies on inhibin knockout mice, suggest enhanced lipolysis and potential benefits in weight management, which are crucial for addressing obesity-related conditions. Additionally, the potential for WVE-007 as a combination therapy with GLP-1R agonists adds to its attractiveness. Although safety remains to be fully established, preliminary indications from similar trials suggest that INHBE might be a safe target. Overall, the combination of promising preclinical results, strong scientific rationale, and potential therapeutic applications underpins Fein’s positive outlook on Wave Life Sciences’ stock.
In another report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $21.00 price target.